Why One Drug Company's Shares More Than Doubled in a Day
Nanexa shares shot up on September 25, 2026, on a deal with Novo Nordisk for injection technology worth up to about €1.17 billion ($1.33 billion). AOL
Other reporting that same day put the jump at 114% and called it a licensing deal, which is like renting out an idea for a fee. Investing.com Both reports describe the same event on the same day. One stresses the share jump and the other stresses the price tag.
The idea in question is PharmaShell, Nanexa's way of putting ultra-thin coats on drugs so one shot lasts longer. That coating method is called atomic layer deposition, and it is used to make long-acting formulations. Nanexa The September 2026 reports say the Novo Nordisk deal centers on injection technology, so this coating system is at the heart of the license.
Nanexa had earlier announced a testing-only deal worth SEK 46.1 million and a direct sale of new shares worth SEK 17.2 million to Novo Nordisk. Nanexa That news came on December 21, 2022. It set a fixed testing fee plus a direct ownership link well before the September 2026 license report.
The broader context here is that "up to" does a lot of work. Headline license values mix firm cash with future payments that only come if goals are met. The €1.17 billion is conditional. How much turns into real cash depends on payment timing, what triggers each payment, who pays to scale up, and how royalties are counted. Until those details are public, think of €1.17 billion as a ceiling, not money in hand.
In my view, the step-by-step path matters most. Test deals pay for information and keep options open. They fund set work while letting Novo Nordisk choose to go on, grow, or stop. Selling shares directly to Novo alongside the tests ties their interests together, but it also leaves Nanexa more exposed to one partner. Moving to a full license shifts the risk from does it work to can it be made the same way every time and filled into long-acting shots reliably.
Looking at what this means for pricing, the 114% rise reflects better odds, not receipt of the full sum. Small drug-delivery stocks trade on future milestone payments cut down for risk, delays, and dependence on one partner. A license with a big drugmaker eases doubts about the science but makes Nanexa more sensitive to decisions it does not control. The earlier SEK 46.1 million test fee and SEK 17.2 million share sale are the only firm money disclosed. Everything above that depends on what happens next.
